Heron Therapeutics, Inc.

Heron Therapeutics wins patent infringement lawsuit for CINVANTI, preventing Fresenius Kabi from launching a generic version until 2035. Stock gains 11% in a week. Heron anticipates Q4 2024 revenue of $37-$43 million, with a positive adjusted EBITDA of $2-$5 million. VAN product launch planned for December 2024, with Prefilled Syringe approval targeted for 2026-2027.

Global equities rebounded in 3Q24, with health care stocks advancing in July and August, then falling in September. Biotechnology stocks led the sector, driven by factors like interest in innovative weight-loss drugs, easing supply constraints, increased health care utilization, and the sector's defensive nature. Key contributors included Applied Therapeutics, ARS Pharmaceuticals, and Revance Therapeutics. The fund's performance was aided by favorable stock selection, particularly in biotechnology, while detractors included HilleVax and Guardant Health. The outlook remains positive for biotechnology, supported by strong fundamentals, innovation, and M&A activity, despite risks from inflation and the IRA drug pricing measures.

The Manufacturers Life Insurance Company increased its Heron Therapeutics stake by 16.0% in Q2, owning 45,771 shares worth $160,000. Other investors also adjusted their holdings, with AQR Capital Management LLC increasing by 1,460.9%, and Caxton Associates LP acquiring a new stake worth $708,000. Needham & Company LLC reiterated a 'buy' rating with a $5.00 price target. Heron Therapeutics' stock opened at $1.76, with a market cap of $265.15 million. The company reported a Q2 EPS of ($0.06), missing estimates by ($0.02), and had revenue of $36.02 million. Heron Therapeutics focuses on enhancing patient lives through therapeutic development.

Squarepoint Ops LLC increased its Heron Therapeutics, Inc. (NASDAQ:HRTX) shares by 369% in Q2, owning 363,700 shares worth $1,273,000. Other investors also adjusted their stakes, with 80.01% of the stock held by institutional investors and hedge funds. Analysts predict Heron Therapeutics will post -0.1 earnings per share for the current fiscal year.

Heron Therapeutics announces FDA approval for Zynrelef's extended-release solution VAN, aiming to simplify aseptic preparation and reduce withdrawal time, potentially enhancing Zynrelef's adoption and patient recovery.

FDA approves Heron Therapeutics' prior approval supplement application for Zynrelef vial access needle, expected to launch in Q4 2024.

Heron Therapeutics Inc. (HRTX) announced FDA approval of the Zynrelef Vial Access Needle (VAN), designed to streamline aseptic preparation and reduce withdrawal time to 20-45 seconds. The VAN replaces the existing vented vial spike with a more user-friendly option, expected to enhance safety and efficiency. Shares rose 4% in pre-market trading to $2.04. The VAN is anticipated for release in Q4 2024.

FDA approves Heron Therapeutics' ZYNRELEF VAN, simplifying aseptic preparation and reducing withdrawal time to 20-45 seconds, expected to launch Q4 2024.